Tilray (TLRY) & Chromadex (CDXC) Head to Head Comparison

Tilray (NASDAQ:TLRY) and Chromadex (NASDAQ:CDXC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Insider & Institutional Ownership

16.2% of Chromadex shares are held by institutional investors. 10.3% of Chromadex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Tilray and Chromadex’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tilray N/A N/A N/A N/A N/A
Chromadex $21.20 million 10.80 -$11.37 million ($0.35) -11.89

Tilray has higher earnings, but lower revenue than Chromadex.


This table compares Tilray and Chromadex’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tilray N/A N/A N/A
Chromadex -82.82% -65.33% -53.31%

Analyst Recommendations

This is a breakdown of current recommendations for Tilray and Chromadex, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray 0 2 1 0 2.33
Chromadex 0 0 1 0 3.00

Tilray presently has a consensus price target of $34.50, suggesting a potential downside of 73.72%. Chromadex has a consensus price target of $8.00, suggesting a potential upside of 92.31%. Given Chromadex’s stronger consensus rating and higher possible upside, analysts clearly believe Chromadex is more favorable than Tilray.


Chromadex beats Tilray on 5 of the 8 factors compared between the two stocks.

About Tilray

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was incorporated in 2018 and is headquartered in Nanaimo, Canada.

About Chromadex

ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California.

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply